Selecta Biosciences (SELB) Tops Q1 EPS by 34c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Selecta Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 7:30 AM EDTPhase 1 trial of SEL-302 remains on track to initiate in the second half of 2022
DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023
Completed underwritten offering, raising approximately $38.7 million in gross proceeds, extending runway into mid-2024
As of April 11, 2022, Selecta had approximately $154.2 million in cash, cash equivalents, restricted cash and marketable securities
Selecta to host conference call today at 8:30 AM ET
WATERTOWN, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a... More
